All Times EDT
Keywords: Contribution of Component, independent drug action
Researchers have long sought to find combinations of cancer drugs that might achieve synergy. However, growing evidence in preclinical data and clinical trial data shows that the treatment effect of most combination therapies can be largely explained by the independent drug action model (i.e., response to combination is the best response to the two components). In this talk, we will introduce the model and discuss its implications to oncology drug development.